

#16B
8/15/02
PATENT

Customer No. 22,852
Attorney Docket No. 3804.0114-02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Jacques MALLET *et al.*) Group Art Unit: 1632
)
Serial No.: 09/578,453) Examiner: R. Shukla
)
Filed: May 26, 2000)
)
For: PHARMACEUTICAL)
COMPOSITIONS AND)
UTILIZATION THEREOF)
PARTICULARLY FOR THE)
TREATMENT OF)
NEURODEGENERATIVE)
DISORDERS)

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

**AMENDMENT AND REQUEST FOR
RECONSIDERATION UNDER 37 C.F.R. § 1.111**

In reply to the Office Action mailed April 11, 2002, Applicants submit the following amendments and remarks and respectfully request reconsideration of the application.

In a separate petition, Applicants have requested and paid the fee for a one-month extension of time. Thus, this Amendment is due on August 11, 2002, and is timely filed.

IN THE CLAIMS:

Please amend claims 16, 19, and 22 as follows:

16. (Amended) A recombinant virus selected from the group consisting of
adenovirus, adeno-associated virus and herpes virus, said recombinant virus

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com